Skip to main content
padlock icon - secure page this page is secure

Free Content The effect of combined tobramycin-clarithromycin on Mycobacterium tuberculosis isolates [Technical note]

Download Article:
(PDF 256.4 kb)
This study investigated the susceptibility of 25 Mycobacterium tuberculosis clinical isolates to tobramycin (TBM) and clarithromycin (CLM). The effect of the drugs administered together was examined for possible synergistic effect. The median minimum inhibitory concentration (MIC) for both drugs was 8 μg/ml. In 36% of the isolates, a decrease of the CLM MIC by a single or two-fold dilution was observed when a sub-inhibitory concentration of TBM was added. The results suggest that both drugs should be investigated further as potential adjuncts to the treatment of resistant tuberculosis, in particular through new drug delivery systems such as the dry powder inhaler allowing high lung deposition.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: MDR-TB; MIC; Mycobacterium tuberculosis; clarithromycin; tobramycin

Document Type: Short Communication

Affiliations: 1: Reference Laboratory of Tuberculosis and Mycobacteria, Scientific Institute of Public Health, Department Institut Pasteur, Brussels, Belgium 2: Laboratoires SMB, Brussels, Belgium

Publication date: 01 August 2009

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more